October 2024 – PROSTATE WARRIORS – The latest news about prostate cancer

Phase 2: Iodine-131 PSMA Radioligand with Enzalutamide Shows Promise in ARROW trial for metastatic castration-resistant prostate cancer (mCRPC)

October 31, 2024/in Clinical Trial, Metastatic, Phase 2/by Max

Phase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity

October 30, 2024/in Clinical Trial, Non-Metastatic, Phase 1/by Max

In Vivo: CRISPR/Cas9 Gene Editing Shows Promise in Prostate Cancer Treatment

October 30, 2024/in CRISPR, Preclinical Research/by Max

In Vitro: Targeted Cancer Therapy with 4armPEG-DD: A Precision Approach for Prostate Cancer

October 30, 2024/in Delivery, Preclinical Research/by Max

In vivo: Menadione Sodium Bisulfite (vitamin K3) as a Pro-Oxidant Therapy for Prostate Cancer

October 30, 2024/in Preclinical Research/by Max

Post-hoc of ARASENS for metastatic hormone sensitive prostate cancer

October 30, 2024/in Clinical Trial, Metastatic, Phase 3/by Max

Darolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial

October 29, 2024/in Clinical Trial, Metastatic, Phase 3/by Max

ARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer

October 29, 2024/in Clinical Trial, Metastatic, Phase 1/by Max